NEXGEL Reports Positive Results from Proof-of-Concept Study for its Diclofenac Hydrogel Pain Treatment
October 25 2022 - 8:00AM
NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL, NXGLW), a
leading provider of ultra-gentle, high-water-content hydrogel
products for healthcare and consumer applications, announced today
positive results from its proof-of-concept study for its diclofenac
hydrogel patches. The patches are designed to treat pain
indications such as arthritis, joint pain, muscle aches and more.
The study compared NEXGEL’s diclofenac hydrogel
patches with the leading commercially available topical treatment.
It assessed the formulations, skin retention and permeation of the
products through the skin. The results revealed NEXGEL’s diclofenac
hydrogel patches delivered an equivalent dose considerably faster
and are longer-acting compared to the current standard-of-care, on
a head-to-head basis. They also showed gentle skin adhesion for
eight to 12 hours.
Diclofenac patches are a nonsteroidal
anti-inflammatory drug (NSAIDs) products that are used to treat
short-term pain due to minor strains, sprains and bruises. The
early proof-of-concept results validate the potential effectiveness
of NEXGEL’s technology in drug delivery patches.
“The early-stage data from this study showcases
the efficiency of our unique hydrogel and its potential for this
product to become a preferred alternative to treat pain as well its
potential utility in a host of other applications,” said Adam Levy,
NEXGEL CEO. “As the Company moves toward next steps of human
clinical studies, we are also seeking potential strategic partners
as we see this as a potential platform technology. We look forward
to updating the market with our progress.”
About NEXGEL, INC.NEXGEL is a
leading provider of ultra-gentle, high-water-content hydrogels for
healthcare and consumer applications. Based in Langhorne, Pa., the
Company has developed and manufactured electron-beam, cross-linked
hydrogels for over two decades. Alongside its strategic partners,
NEXGEL has formulated more than 200 different combinations to bring
natural ingredients to gentle skin patches that can be worn for
long periods of time with little to no irritation.
Forward-Looking Statement
This press release contains "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended (the "Exchange Act") (which Sections were
adopted as part of the Private Securities Litigation Reform Act of
1995). Statements preceded by, followed by or that otherwise
include the words "believe," "anticipate," "estimate," "expect,"
"intend," "plan," "project," "prospects," "outlook," and similar
words or expressions, or future or conditional verbs, such as
"will," "should," "would," "may," and "could," are generally
forward-looking in nature and not historical facts. These
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause the Company's
actual results, performance, or achievements to be materially
different from any anticipated results, performance, or
achievements for many reasons including the impact of the COVID-19
pandemic. The Company disclaims any intention to, and undertakes no
obligation to, revise any forward-looking statements, whether as a
result of new information, a future event, or otherwise. For
additional risks and uncertainties that could impact the Company's
forward-looking statements, please see the Company's Annual Report
on Form 10-K for the year ended December 31, 2021, including but
not limited to the discussion under "Risk Factors" therein, which
the Company filed with the SEC and which may be viewed
at http://www.sec.gov/.
Investor Contact:Valter Pinto,
Managing DirectorKCSA Strategic
Communications212.896.1254valter@kcsa.com
Media Contacts:Raquel Cona / Michaela
FawcettKCSA Strategic Communications212.896.1204 /
978.995.4683rcona@kcsa.com / mfawcett@kcsa.com
NexGel (NASDAQ:NXGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
NexGel (NASDAQ:NXGL)
Historical Stock Chart
From Apr 2023 to Apr 2024